<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-4157</journal-id>
<journal-title><![CDATA[Biomédica]]></journal-title>
<abbrev-journal-title><![CDATA[Biomédica]]></abbrev-journal-title>
<issn>0120-4157</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-41572018000400486</article-id>
<article-id pub-id-type="doi">10.7705/biomedica.v38i4.3988</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación de la intercambiabilidad in vitro de diferentes marcas de tabletas de diclofenaco sódico disponibles en el mercado colombiano]]></article-title>
<article-title xml:lang="en"><![CDATA[In vitro evaluation of the interchangeability of different brands of diclofenac sodium tablets available in the Colombian market]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Matiz]]></surname>
<given-names><![CDATA[Germán Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Trujillo]]></surname>
<given-names><![CDATA[Mary]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[Diana Alexandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Baena]]></surname>
<given-names><![CDATA[Yolima]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Colombia Facultad de Ciencias Departamento de Farmacia]]></institution>
<addr-line><![CDATA[Bogotá D.C]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional de Colombia Facultad de Ciencias Departamento de Farmacia]]></institution>
<addr-line><![CDATA[Bogotá D.C]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>38</volume>
<numero>4</numero>
<fpage>486</fpage>
<lpage>495</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-41572018000400486&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-41572018000400486&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-41572018000400486&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción. El diclofenaco sódico se clasifica como un antiinflamatorio no esteroide. Dado que es de venta libre, el paciente no tiene ningún seguimiento por parte de los equipos de salud, y como sus fuentes son múltiples, es necesario establecer la equivalencia entre ellas en estudios in vitro, que son los más prácticos y plantean un menor compromiso ético.  Objetivos. Determinar la intercambiabilidad de diferentes marcas comerciales de diclofenaco sódico comparadas con el producto innovador mediante un estudio in vitro de tabletas comerciales de 50 mg, según los lineamientos del Sistema de Clasificación Biofarmacéutica (SCB).  Materiales y métodos. Se desarrollaron pruebas físicas y químicas siguiendo las indicaciones de laedición 39 de la United States Pharmacopeia (USP). Para la cuantificación, se validó una metodología analítica según lo establecido en la mencionada farmacopea y la guía Q2 del International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Los perfiles de disolución y sus análisis se rigieron por lo establecido por la Organización Mundial de la Salud y las normas nacionales.  Resultados. Todos los productos aprobaron las pruebas físicas. En cuanto a la disolución, la etapa ácida también fue superada por todas las marcas, pero una marca falló en la etapa alcalina. El análisis de similitud reveló que solo un producto fue equivalente al innovador y tres fueron supradisponibles, aunque dichas marcas también podrían considerarse equivalentes al producto innovador.  Conclusiones. De las ocho marcas evaluadas, tres no cumplieron totalmente con la prueba de valoración del principio activo y del porcentaje de disolución; solo una marca fue intercambiable con el producto innovador y tres fueron supradisponibles comparadas con este, por lo cual no constituyen un riesgo para el paciente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Diclofenac sodium is classified as a non-steroidal anti-inflammatory drug. As diclofenac is an over-the-counter drug, its use among patients cannot be monitored by health teams in follow-up sessions. Given the multiple sources of diclofenac sodium, their interchangeability must be investigated, particularly in the form of in vitro studies, which are the most practical research type and entail minimal ethical commitment.  Objectives: To determine the interchangeability of the different commercial brands of diclofenac sodium relative to the innovative product, this work carries out an in vitro study of eight commercial products of diclofenac sodium (50 mg) following the guidelines of the Biopharmaceutical Classification System.  Materials and methods: Physical and chemical tests were developed following the guidelines of the 39th edition of the United States Pharmacopoeia. An analytical methodology was validated for the quantification of diclofenac according to the current pharmacopoeia and the Q2 guideline ofthe International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Dissolution profiles and their analyseswere governed by the regulations established by the World Health Organization and the national regulations.  Results: All the products passed the physical tests. In the dissolution assays, the acid stage was overcome by all brands, but in the alkaline stage, one brand failed. The analysis of the similarities revealed that only one product was equivalent to the innovator and that three were supra-available, although these brands could also be considered equivalent to the innovator.  Conclusions: Of the eight brands evaluated, three failed the test forthe active principle and the percentage of dissolution. Only one brand was found to be interchangeable with the innovator, and three were identified to besupra-availableand, thus, they do not present a risk for patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[diclofenaco]]></kwd>
<kwd lng="es"><![CDATA[medicamentos bioequivalentes, intercambiabilidad de medicamentos]]></kwd>
<kwd lng="es"><![CDATA[liberación de fármacos]]></kwd>
<kwd lng="es"><![CDATA[disolución]]></kwd>
<kwd lng="en"><![CDATA[Diclofenac]]></kwd>
<kwd lng="en"><![CDATA[bioequivalent drugs]]></kwd>
<kwd lng="en"><![CDATA[interchange of drugs]]></kwd>
<kwd lng="en"><![CDATA[drug liberation]]></kwd>
<kwd lng="en"><![CDATA[dissolution]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oser]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Melnick]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hochberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Physiological availability of the vitamins. Study of methods for determining availability of vitamins in pharmaceutical products]]></article-title>
<source><![CDATA[Ind Eng Chem Anal Ed]]></source>
<year>1945</year>
<volume>17</volume>
<page-range>405-11</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Melnick]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Oser]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Physiological availability of the vitamins]]></article-title>
<source><![CDATA[Vitamins &amp; Hormones]]></source>
<year>1947</year>
<volume>5</volume>
<page-range>39-92</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[History of pharmacokinetics]]></article-title>
<source><![CDATA[Pharmacol Ther]]></source>
<year>1981</year>
<volume>12</volume>
<page-range>537-62</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Resolución 1124, anexo técnico 1. Guía de biodisponibilidad y bioequivalencia]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>Organización Panamericana de la Salud</collab>
<source><![CDATA[Guía para la implementación de estrategias de medicamentos genéricos en los países de América Latina y El Caribe como mecanismo para mejorar el acceso a los medicamentos]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lawrence]]></surname>
<given-names><![CDATA[XY]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[BV]]></given-names>
</name>
</person-group>
<source><![CDATA[FDA Bioequivalence Standards]]></source>
<year>2014</year>
<edition>1a ed</edition>
<page-range>465</page-range><publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Food and Drugs Administration</collab>
<source><![CDATA[Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products-general considerations. FDA]]></source>
<year>2003</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Orobio]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Baena]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio comparativo de la liberación in vitro de metformina, a partir de dos productos multifuente de liberación inmediata, comercializados en Colombia]]></article-title>
<source><![CDATA[Rev Colomb Cienc Quím Farm]]></source>
<year>2013</year>
<volume>42</volume>
<page-range>169-89</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>Asociación Nacional de Empresarios de Colombia</collab>
<collab>ANDI</collab>
<source><![CDATA[Cifras de la industria farmacéutica]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>Oficina Económica y Comercial de la Embajada de España en Bogotá</collab>
<collab>Bairexport</collab>
<source><![CDATA[El sector de productos farmacéuticos para usohumano en Colombia]]></source>
<year>2005</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<collab>Instituto Nacional de Vigilancia de Medicamentos y Alimentos</collab>
<collab>INVIMA</collab>
<source><![CDATA[Normas farmacológicas]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Garavito]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Condición de venta de analgésicos antiinflamatorios no esteroides, legalmente autorizados para su comercialización en Colombia. Estrategias de uso racional]]></article-title>
<source><![CDATA[Rev Colomb Cienc Quím Farm]]></source>
<year>2013</year>
<volume>42</volume>
<page-range>145-68</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chuasuwan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Binjesoh]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Polli]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Amidon]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Junginger]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biowaiver monographs for immediate release solid oral dosage forms: Diclofenac sodium and diclofenac potassium]]></article-title>
<source><![CDATA[J Pharm Sci]]></source>
<year>2009</year>
<volume>98</volume>
<page-range>1206-19</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<collab>United States Pharmacopeial Convention</collab>
<source><![CDATA[Farmacopea de los Estados Unidos de América : USP 39 : Formulario nacional : NF 34. Formulario Nacional, USP, USP 39 - NF 34]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Rockville, Md. ]]></publisher-loc>
<publisher-name><![CDATA[United States Pharmacopeial Convention]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>International Committee for Harmonization</collab>
<collab>ICH</collab>
<source><![CDATA[Guidance for Industry: Q2B Validation of Analytical Procedures: Methodology]]></source>
<year>1996</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&#8217;Hara]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dunne]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Devane]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review of methods used to compare dissolution profile data]]></article-title>
<source><![CDATA[Pharm Sci Technol Today]]></source>
<year>1998</year>
<volume>1</volume>
<page-range>214-23</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Tsong]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sathe]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J-P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f2]]></article-title>
<source><![CDATA[Pharm Res]]></source>
<year>1998</year>
<volume>15</volume>
<page-range>889-96</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matiz]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio comparativo de la calidad biofarmacéutica de marcas comerciales y multifuentes de tabletas de captopril y losartán del mercado colombiano]]></article-title>
<source><![CDATA[Rev Colomb Ciencias Quim Farm]]></source>
<year>2014</year>
<volume>43</volume>
<page-range>217-33</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Matiz]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Pájaro]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio biofarmacéutico comparativo de marcas comerciales de tabletas de ciprofloxacino disponibles en el mercado colombiano]]></article-title>
<source><![CDATA[Rev Salud Pública (Bogotá)]]></source>
<year>2012</year>
<volume>14</volume>
<page-range>695-709</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The concept of dissolution efficiency]]></article-title>
<source><![CDATA[J Pharm Pharmacol]]></source>
<year>1975</year>
<volume>27</volume>
<page-range>48-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serra]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Storpirtis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparação de perfis de dissolução da cefalexina através de estudos de cinética e eficiência de dissolução (ED por cento)]]></article-title>
<source><![CDATA[Rev Bras Ciênc Farm]]></source>
<year>2007</year>
<volume>43</volume>
<page-range>79-88</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villaroel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Clement]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sealy]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Löbenberg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Montane]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Maharaj]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing the dissolution profiles of seven metformin formulations in simulated intestinal fluid]]></article-title>
<source><![CDATA[Dissolution Technologies]]></source>
<year>2015</year>
<volume>22</volume>
<page-range>17-22</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Podczeck]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT)]]></article-title>
<source><![CDATA[Int J Pharm]]></source>
<year>1993</year>
<volume>97</volume>
<page-range>93-100</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Azarmi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Roa]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Löbenberg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current perspectives in dissolution testing of conventional and novel dosage forms]]></article-title>
<source><![CDATA[Int J Pharm]]></source>
<year>2007</year>
<volume>328</volume>
<page-range>12-21</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<collab>Food and Drugs Administration</collab>
<source><![CDATA[Waiver of in vivo bioavailability and bioequivalence studies for imme- diaterelease solid oral dosage forms based on a biopharmaceutics classification system: Guidance for industry]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frutos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ocaña]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Técnicas de remuestreo en la comparación de curvas de disolución de fármacos]]></article-title>
<source><![CDATA[An Real Acad Farm]]></source>
<year>2011</year>
<volume>77</volume>
<page-range>1-19</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Dorantes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gold]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pham]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Scientific and regulatory standards for assessing product performance using the similarity factor, f2]]></article-title>
<source><![CDATA[AAPS J]]></source>
<year>2015</year>
<volume>17</volume>
<page-range>301-6</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wadher]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kakde]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Umekar]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of a sustained-release tablet of metformin hydrochloride containing hydrophilic eudragit and ethyl cellulose polymer]]></article-title>
<source><![CDATA[International Journal of Comprehensive Pharmacy]]></source>
<year>2011</year>
<volume>2</volume>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Lineamientos para la implementación de la política de seguridad del paciente en la República de Colombia]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hinz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chevts]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Renner]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wuttke]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rau]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bioavailability of diclofenac potassium at low doses]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2005</year>
<volume>59</volume>
<page-range>80-4</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<collab>World Health Organization Expert Committee on Specifications for Pharmaceutical Preparations</collab>
<article-title xml:lang=""><![CDATA[Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability]]></article-title>
<source><![CDATA[WHO Technical Report Series]]></source>
<year></year>
<numero>992</numero>
<issue>992</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
